enGene Therapeutics
ENGN
30 hedge funds and large institutions have $307M invested in enGene Therapeutics in 2024 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 7 closing their positions.
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
1.18% more ownership
Funds ownership: 72.64% → 73.83% (+1.2%)
3% less funds holding
Funds holding: 31 → 30 (-1)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
43% less capital invested
Capital invested by funds: $536M → $307M (-$229M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$26.9M |
| 2 |
SOCM
SR One Capital Management
Wayne,
Pennsylvania
|
+$6.41M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
+$5.13M |
| 4 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$3.38M |
| 5 |
VA
VR Adviser
New York
|
+$3.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
-$21.2M |
| 2 |
DM
Deerfield Management
New York
|
-$13.6M |
| 3 |
PA
Perceptive Advisors
New York
|
-$2.55M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$2.45M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.78M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| $75K | – | – | – |
|
27
UBS Group
Zurich,
Switzerland
| $31.8K | +$43.2K | +3,370 | New |
|
28
Wells Fargo
San Francisco,
California
| $9.17K | +$12.5K | +972 | New |
|
|
ACM
29
ADAR1 Capital Management
Austin,
Texas
| $5.66K | +$7.7K | +600 | New |
|
30
Morgan Stanley
New York
| $547 | +$641 | +50 | +625% |
|
|
CC
31
Commodore Capital
New York
| – | -$21.2M | -1,250,000 | Closed |
|
|
DM
32
Deerfield Management
New York
| – | -$13.6M | -800,000 | Closed |
|
|
ACP
33
Altitude Crest Partners
Stamford,
Connecticut
| – | -$2.04M | -120,289 | Closed |
|
|
PAMP
34
Polar Asset Management Partners
Toronto,
Ontario, Canada
| – | -$1.1M | -65,225 | Closed |
|
|
CSS
35
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$165K | -9,757 | Closed |
|
36
JP Morgan Chase
New York
| – | -$4.9K | -289 | Closed |
|
37
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$237 | -14 | Closed |
|
ENGN Hedge Fund Activity: Q2 2024 in Review
30 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in enGene Therapeutics (ENGN) for Q2 2024, worth a combined $307M — down 43% from $536M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ENGN and 6 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 8 added.
The largest buyer was Adage Capital Partners, adding an estimated $26.9M. The largest seller was Commodore Capital, exiting entirely with an estimated $21.2M sold.
- 30 institutional investors held enGene Therapeutics (ENGN) as of Q2 2024, down from 31 in Q1 2024.
- Funds reported $307M of enGene Therapeutics stock for Q2 2024, down 43% quarter-over-quarter.
- 6 funds opened new enGene Therapeutics positions in Q2 2024 and 7 closed out, a net change of -1 holder.
- The largest enGene Therapeutics buyer in Q2 2024 was Adage Capital Partners, an estimated $26.9M added.
- The largest enGene Therapeutics seller in Q2 2024 was Commodore Capital, an estimated $21.2M sold.
Based on aggregated 13F filings for Q2 2024.